Clinical Trial: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Study Status: Completed
Recruit Status: RECRUITING
Condition: Advanced Renal Cell Carcinoma
Study Type: INTERVENTIONAL
Official Title: Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Brief Summary:
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC.The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B. Patients in all IMDC Risk Groups are included.This study utilizes a Simon's two stage design which is described in the…
Read more